Reported Wednesday, China's NMPA Approves GenFleet And Verastem Oncology's GFH375 For KRAS G12D Phase I/II Trials
Reported Wednesday, China's NMPA Approves GenFleet And Verastem Oncology's GFH375 For KRAS G12D Phase I/II Trials
據週三報道，中國國家藥品監督管理局批准GenFleet和verastem公司的GFH375進行KRASG12D分Ⅰ/Ⅱ期臨床試驗。
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. G12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet.
GenFleet Therapeutics是一家臨床生物技術公司，致力於腫瘤學和免疫學領域的尖端治療方案。該公司宣佈，中國國家藥品監督管理局已批准GFH375（VS-7375）的臨床試驗申請，該試驗爲開放標籤、多中心I/II期研究，針對具有KRAS G12D突變的晚期實體腫瘤患者。G12D突變是人類腫瘤中檢測到的最普遍的KRAS突變，尚未批准任何G12D靶向治療。